Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.49 |
| ▸ | CA1 | P00915 | 8/20 | 0.49 |
| ▸ | CA9 | Q16790 | 5/20 | 0.49 |
| ▸ | CA12 | O43570 | 3/20 | 0.49 |
| ▸ | CA6 | P23280 | 2/20 | 0.49 |
| ▸ | CA5A | P35218 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15212564 | 0.79 | CA2 (0.49) | CA2CA1CA9CA12CA6 | |
| SCHEMBL1575609 | 0.77 | EPHB4 (0.52) | CA2CA1CA9CA12CA6 | |
| SCHEMBL7677416 | 0.76 | MAPK10 (0.56) | MKNK1LMNAMEN1KMT2AKDM4E | |
| SCHEMBL2447841 | 0.73 | AURKA (0.58) | MKNK1KDM4EALDH1A1MAPK10AURKA | |
| SCHEMBL27564107 | 0.72 | JAK2 (0.46) | MKNK1LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL27998656 | 0.72 | MAPK10 (0.56) | MKNK1LMNAMEN1KMT2AKDM4E | |
| SCHEMBL28669238 | 0.72 | MEN1 (0.46) | MKNK1MEN1KMT2AKDRMAPK10 | |
| SCHEMBL4391902 | 0.72 | MAPK10 (0.56) | MKNK1MEN1KMT2AKDRMAPK10 | |
| SCHEMBL5186223 | 0.72 | PDGFRB (0.51) | CA2CA1CA9CA12CA6 | |
| SCHEMBL30471271 | 0.71 | TYK2 (0.42) | MKNK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691986-B2 | PTEFB inhibiting macrocyclic compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-04 | — | — | US | disclosed |
| US-20220281892-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-08 | — | — | US | disclosed |
| US-20220267353-A1 | PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-08-25 | — | — | US | disclosed |
| US-11254690-B2 | PTEFb inhibiting macrocyclic compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-02-22 | — | — | US | disclosed |
| US-11242356-B2 | PTEFb inhibiting macrocyclic compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2022-02-08 | — | — | US | disclosed |
| EP-3601253-B1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AG (DE) | 2021-09-15 | — | — | EP | disclosed |
| CN-108290903-B | Novel macrocyclic sulfondiimine compounds | 拜耳医药股份有限公司 | 2021-09-03 | — | — | CN | disclosed |
| CN-108368129-B | Modified macrocyclic compounds | 拜耳医药股份有限公司 | 2021-08-17 | — | — | CN | disclosed |
| US-20200347079-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-11-05 | — | — | US | disclosed |
| EP-3359544-B1 | NOVEL MODIFIED MACROCYCLIC COMPOUNDS | Bayer Pharma AG (DE) | 2020-08-12 | — | — | EP | disclosed |
| US-20150368209-A1 | 4-Pyrimidinylamino-benzenesulfonamide derivatives and their use for the inhibition of polo-like kinase 1 (PLK1) for the treatment of cancer and their use for the treatment of bacterial infections | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) | 2015-12-24 | — | — | US | disclosed |
| EP-2941428-A1 | 4-PYRIMIDINYLAMINO-BENZENESULFONAMIDE DERIVATIVES AND THEIR USE FOR THE INHIBITION OF POLO-LIKE KINASE 1 (PLK1) FOR THE TREATMENT OF CANCER AND THEIR USE FOR THE TREATMENT OF BACTERIAL INFECTIONS | Vichem Chemie Kutató KFT (HU) | 2015-11-11 | — | — | EP | disclosed |
| EP-2941428-A1 | 4-PYRIMIDINYLAMINO-BENZENESULFONAMIDE DERIVATIVES AND THEIR USE FOR THE INHIBITION OF POLO-LIKE KINASE 1 (PLK1) FOR THE TREATMENT OF CANCER AND THEIR USE FOR THE TREATMENT OF BACTERIAL INFECTIONS | Vichem Chemie Kutató KFT (HU) | 2015-11-11 | — | — | EP | disclosed |
| WO-2015155197-A1 | NOVEL MACROCYCLIC COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015150273-A1 | DISUBSTITUTED 5-FLUORO PYRIMIDINE DERIVATIVES CONTAINING A SULFONDIIMINE GROUP | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015136028-A1 | 5-FLUORO-N-(PYRIDIN-2-YL)PYRIDIN-2-AMINE DERIVATIVES CONTAINING A SULFONE GROUP | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-17 | — | — | WO | disclosed |
| WO-2014106762-A1 | 4-PYRIMIDINYLAMINO-BENZENESULFONAMIDE DERIVATIVES AND THEIR USE FOR THE INHIBITION OF POLO-LIKE KINASE 1 (PLK1) FOR THE TREATMENT OF CANCER AND THEIR USE FOR THE TREATMENT OF BACTERIAL INFECTIONS | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2014-07-10 | — | — | WO | disclosed |
| WO-2014106762-A1 | 4-PYRIMIDINYLAMINO-BENZENESULFONAMIDE DERIVATIVES AND THEIR USE FOR THE INHIBITION OF POLO-LIKE KINASE 1 (PLK1) FOR THE TREATMENT OF CANCER AND THEIR USE FOR THE TREATMENT OF BACTERIAL INFECTIONS | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2014-07-10 | — | — | WO | disclosed |
| EP-1951684-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | Targegen, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007053452-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11242356-B2 | PTEFb inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | CA2 4825/4885CA1 4830/4885CA9 4715/4885 |
| US-20150368209-A1 | 4-Pyrimidinylamino-benzenesulfonamide derivatives and their use for the inhibition of polo-like kinase 1 (PLK1) for the treatment of cancer and their use for the treatment of bacterial infections | PLK1, PLK2, PLK4 | CA2 4649/4885CA1 4877/4885CA9 4495/4885 |
| US-20220281892-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | PCLAF, PKD1, RHEB | CA2 4823/4885CA1 4850/4885CA9 4742/4885 |
| US-20200347079-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | PCLAF, PKD1, RHEB | CA2 4823/4885CA1 4850/4885CA9 4742/4885 |
| US-11254690-B2 | PTEFb inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | CA2 4825/4885CA1 4830/4885CA9 4715/4885 |
| US-11691986-B2 | PTEFB inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | CA2 4825/4885CA1 4830/4885CA9 4715/4885 |
| US-20220267353-A1 | PTEFB INHIBITING MACROCYCLIC COMPOUNDS | PCLAF, PPIB, RHEB | CA2 4825/4885CA1 4830/4885CA9 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.